fedratinib
Ligand Summary
Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). Fedratinib is a JAK2-selective inhibitor with higher inhibitory activity for JAK2 over family members JAK1, JAK3 and TYK2. Abnormal activation of JAK2 is associated with myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera.
UNII: 6L1XP550I6
PubChem: 16722836
Guide to Pharmacology: 5716
ChEMBL: CHEMBL1287853
DrugCentral: 5347
LyCHI: GUJY5FTRMBSB
Target Activities
45 Activities
Items per page:
10
1 – 10 of 45
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
Kd | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
Kd | ||||||
Kd | ||||||
Kd | ||||||
Kd | ||||||
Kd | ||||||